STOCK TITAN
  1. Home
  2. News
  3. IVBIY

Innovent Biologi Stock Price, News & Analysis

IVBIY OTC

Welcome to our dedicated page for Innovent Biologi news (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologi stock.

Innovent Biologics (IVBIY) is a global biopharmaceutical leader developing precision therapies for oncology, autoimmune disorders, and chronic diseases. This page provides investors and healthcare professionals with timely updates on clinical advancements, regulatory milestones, and strategic partnerships shaping the company's trajectory.

Access official press releases and curated analysis covering key developments including clinical trial results, drug approval updates, and collaboration announcements. Our repository simplifies tracking Innovent's progress in bringing innovative treatments to market through its robust pipeline of immune checkpoint inhibitors and targeted biologics.

Content spans financial disclosures, manufacturing expansions, and research breakthroughs across therapeutic areas. Bookmark this page for streamlined monitoring of Innovent's contributions to advancing treatments for lung cancer, metabolic conditions, and ophthalmologic diseases through its global network of 30+ healthcare partners.

News

2025 ASCO Presentation: Innovent Biologics Announces Updated Data of IBI354 (Novel anti-HER2 ADC) From the Phase 1/2 Clinical Study in Advanced Ovarian Cancer, Breast Cancer and Other Solid Tumors

Rhea-AI Summary
Innovent Biologics presented updated Phase 1/2 clinical data for IBI354, their novel anti-HER2 ADC, at ASCO 2025. The study enrolled 368 patients with advanced solid tumors, including 178 breast cancer, 92 ovarian cancer, and other tumor types. In HER2-positive breast cancer (n=88), IBI354 showed a 59.1% ORR and 90.9% DCR, with 9mg/kg dose achieving 72.4% ORR. Median PFS was 14.1 months. In ovarian cancer (n=92), the treatment demonstrated 41.2% ORR and 82% DCR, with 12mg/kg dose reaching 55% ORR. The drug showed a favorable safety profile with only 1.9% incidence of ILD (all grade 1-2), and 27.4% of patients experiencing grade 3+ TRAEs. The Phase 3 study for platinum-resistant ovarian cancer has been initiated, marking a significant milestone in Innovent's IO+ADC oncology strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Date of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from Phase 1 Clinical Studies in Advanced Colorectal Cancer

Rhea-AI Summary
Innovent Biologics presented Phase 1 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at ASCO 2025. The study evaluated IBI363 both as monotherapy and in combination with bevacizumab for advanced colorectal cancer. As monotherapy (n=68), IBI363 achieved a median overall survival of 16.1 months, significantly higher than historical standard treatments (6.4-9.3 months), with a confirmed ORR of 13.6% at 1 mg/kg Q2W. In combination with bevacizumab (n=73), the treatment showed a 15.1% confirmed ORR and 61.6% disease control rate, with median PFS of 4.7 months. Notably, patients without liver metastases showed better outcomes with 31.3% ORR and 7.4 months PFS. The safety profile was manageable, with 27.9% and 35.6% of patients experiencing Grade 3+ TRAEs in monotherapy and combination therapy, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

ASCO 2025 Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α -bias Bispecific Antibody Fusion Protein) from Phase 1 and 2 Clinical Studies on Immunotherapy-treated Advanced Malignant Melanoma

Rhea-AI Summary
Innovent Biologics presented breakthrough Phase 1/2 clinical data for IBI363, a first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein, at ASCO 2025. The drug showed promising results in treating immunotherapy-pretreated advanced melanoma, particularly in 'cold tumor' subtypes. Among 31 patients treated with 1 mg/kg Q2W, the confirmed objective response rate was 23.3%, with disease control rate reaching 76.7%. The median progression-free survival was 5.7 months, and overall survival was 14.8 months, with a 61.5% 12-month survival rate. IBI363 demonstrated a manageable safety profile, with mostly Grade 1-2 adverse events. A pivotal Phase 2 registration trial comparing IBI363 to pembrolizumab in 180 treatment-naive patients is now underway, marking a significant advancement in melanoma treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News

Innovent Announces a Phase 3 Study of Picankibart (Anti-IL-23p19 Antibody) Completes First Participant Dosing, Exploring Biologics Switching Treatment for Psoriasis Patients with Prior Inadequate Response to Anti-IL-17 Antibodies

Rhea-AI Summary
Innovent Biologics has initiated a Phase 3 clinical trial for picankibart, their anti-IL-23p19 antibody, with the first participant successfully dosed. The study will evaluate the efficacy of switching to picankibart in psoriasis patients who showed inadequate response to anti-IL-17 antibody treatment. The trial will enroll approximately 310 participants in a 1:1 randomization ratio. Previous Phase 2 results showed promising outcomes, with 48.2% of participants achieving the primary endpoint at week 16, and 54.2% maintaining response through week 44. Notably, 64.6% of participants with baseline sPGA ≥ 2 and BSA ≥ 3% achieved sPGA of 0 or 1, while 16.9% achieved complete skin clearance. Picankibart's new drug application for moderate-to-severe plaque psoriasis was submitted to NMPA in September 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)

Rhea-AI Summary
Innovent Biologics announces the publication of Phase 3 GLORY-1 clinical study results for mazdutide, their dual GCG/GLP-1 receptor agonist, in The New England Journal of Medicine. The study, involving 610 Chinese adults with overweight or obesity, demonstrated significant weight reduction over 48 weeks. The mazdutide 6 mg dose achieved -14.84% weight reduction compared to -0.47% for placebo. 84% of participants in the 6 mg group achieved ≥5% weight reduction at week 32. The drug also showed improvements in cardiovascular and metabolic indicators, including significant reductions in liver fat content (up to -80.24%). Common side effects included nausea, diarrhea, and vomiting, mostly mild to moderate. Mazdutide, ranked among FIERCE Pharma's 2025 Top 10 Most Anticipated Drugs, is expected to launch in China this year for weight management and glycemic control.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

Rhea-AI Summary
Innovent Biologics (IVBIY) has released its 2024 ESG Report, showcasing significant achievements in sustainable development and innovation. The company achieved an MSCI ESG rating of AAA, becoming the only biotech in China and one of three globally with this distinction. Key highlights include: 15 commercialized products benefiting 5 million patients, a robust pipeline with 3 NDAs under review and 19 molecules in development, and 6 medicines included in China's National Reimbursement Drug List. The company operates 140,000L of production capacity with plans to expand to 230,000L. Innovent demonstrated strong diversity metrics with 51% female employees and 44.2% women in management positions. Environmental achievements include a 29% reduction in energy consumption and 22% reduction in fresh water use per unit of production compared to the previous year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.07%
Tags
none
News

Second Head-to-head Phase 3 Study of Mazdutide versus Semaglutide Completes First Participant Dosing in Adults in China with Overweight or Obesity Accompanied Fatty Liver Disease (GLORY-3)

Rhea-AI Summary
Innovent Biologics has initiated the GLORY-3 Phase 3 clinical trial comparing mazdutide (IBI362) to semaglutide in Chinese adults with overweight/obesity and fatty liver disease (MAFLD). The study will enroll approximately 470 participants randomized 1:1 to receive mazdutide 9mg or semaglutide 2.4mg, measuring changes in liver fat content and body weight over 48 weeks. Previous Phase 2 results showed mazdutide 9mg achieved an 18.6% (17.8kg) placebo-adjusted weight reduction and a 73.3% reduction in liver fat content after 24 weeks in participants with baseline LFC≥5%. As a dual GCG/GLP-1 receptor agonist, mazdutide offers potential advantages over single GLP-1 receptor agonists through enhanced lipolysis and fatty acid oxidation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News

Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema

Rhea-AI Summary
Innovent Biologics (IVBIY) has initiated Phase 2 clinical trials for efdamrofusp alfa (IBI302), a first-in-class bispecific fusion protein targeting both VEGF and complement for treating diabetic macular edema (DME). The study will enroll 150 patients randomized into three groups: IBI302 4mg, IBI302 8mg, and Faricimab 6mg. The trial marks the first global comparison between two dual-target agents in DME treatment. Previous clinical studies have shown that high-dose (8mg) efdamrofusp alfa demonstrates significant improvements in visual acuity and retinal edema, with potential for extended dosing intervals of 12-16 weeks. The drug aims to address the limitations of current DME treatments, which require frequent injections every 4-8 weeks. The market opportunity is substantial, with China having over 140 million diabetic patients, of which approximately one-third develop diabetic retinopathy. The DME prevalence rate ranges from 7% to 14% among these patients, suggesting an estimated 4-5 million DME patients in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
clinical trial fda approval
-
News

Innovent Announces Oral Presentation of Full Phase 2 Clinical Data for Efdamrofusp Alfa (IBI302), First-in-class anti-VEGF/complement Bispecific Fusion Protein at ARVO 2025

Rhea-AI Summary
Innovent Biologics presented promising 1-year Phase 2 clinical trial results for efdamrofusp alfa (IBI302), their first-in-class anti-VEGF/complement bispecific fusion protein, at ARVO 2025. The study involved 132 patients with neovascular age-related macular degeneration (nAMD), comparing two IBI302 doses (6.4mg and 8.0mg) against Aflibercept 2.0mg. Key findings showed that over 80% of IBI302 patients maintained visual benefits with 12-week dosing intervals. Both IBI302 doses demonstrated noninferiority to Aflibercept, with visual acuity improvements of +10.8 and +11.3 letters at week 52. The drug showed superior anatomical improvements and potentially reduced macular atrophy incidence by 40% compared to Aflibercept (4.9% vs 8.3%). No new safety concerns were identified, positioning IBI302 as a promising treatment option with extended dosing intervals for nAMD patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.71%
Tags
clinical trial fda approval
News

Innovent Announces First Patient Dosed in Phase 1 Study of IBI3020, Global First-in-class Dual Payload CEACAM5 ADC, in Patients with Advanced Malignancies

Rhea-AI Summary

Innovent Biologics has achieved a significant milestone with the first patient dosing of IBI3020, a groundbreaking dual-payload CEACAM5 ADC, in a Phase 1 clinical trial for advanced solid tumors. This marks a global first-in-class development in cancer treatment technology.

The multi-regional Phase 1 study, approved in both China and the U.S., will evaluate the safety, tolerability, and preliminary efficacy of IBI3020. The drug, developed from Innovent's proprietary DuetTx® dual-payload ADC platform, works by selectively binding to CEACAM5-expressing tumor cells and releasing two types of cytotoxic payloads to kill cancer cells.

Preclinical studies have shown promising results, with IBI3020 demonstrating strong antitumor activity and manageable safety profiles. The drug targets CEACAM5, a protein overexpressed in various solid tumors including colorectal cancer, non-squamous lung cancer, gastric cancer, and pancreatic cancer, while showing limited expression in healthy tissues.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of Innovent Biologi (IVBIY)?

The current stock price of Innovent Biologi (IVBIY) is $29 as of May 23, 2025.

What is the market cap of Innovent Biologi (IVBIY)?

The market cap of Innovent Biologi (IVBIY) is approximately 8.0B.
Stock IVBIY logo
Innovent Biologi

OTC:IVBIY

IVBIY Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

IVBIY Stock Data

7.97B
91.64M
Biotechnology
Healthcare
Link
China
Suzhou